Publicacions científiques

Frontzek K, Carta M, Losa M, Epskamp M, Meisl G, Anane A, Brandel JP, Camenisch U, Castilla J, Haïk S, Knowles T, Lindner E, Lutterotti A, Minikel EV, Roiter I, Safar JG, Sanchez-Valle R, Žáková D, Hornemann S, Aguzzi A; THAUTAN-MC Study Group.

Null Hypothesis

Any publicació:

2020

Número de revista:

Neurology vol. 95 n. 14

https://n.neurology.org/content/95/14/e2028

Article

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion

Autor/s:

Tzartos JS, Valsami S, Tzanetakos D, Stergiou C, Dandoulaki M, Barbarousi D, Psimenou E, Velonakis G, Stefanis L, Kilidireas K.

Clinical/Scientific Notes

Any publicació:

2020

Número de revista:

Neurology Neuroimmunology & Neuroinflammation vol. 7 n. 3

https://nn.neurology.org/content/7/3/e711.long

Una iniciativa de:

Cercador

Author response: Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease

Author response: Value of witness observations in the differential diagnosis of transient loss of consciousness

Author response: Variability in reported physician practices for brain death determination

Author response: WMH and long-term outcomes in ischemic stroke: A systematic review and meta-analysis

Authors' response to letter to the editor by Zhiqiang Wu, Jiazhang Wu, and Zhibin Lan. Clark K, Goldstein RL, Hart JE, Teylan M, Lazzari AA, Gagnon DR, Tun CG, Garshick E.

Authors’ response

Author’s Response to Letter to the Editor

Author’s Response to Letter to the Editor

Autoantibodies against the prion protein in individuals with PRNP mutations.

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion

Trobes a faltar informació? Fes-nos arribar els teus suggeriments!